BR112012008848A2 - composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas - Google Patents
composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidasInfo
- Publication number
- BR112012008848A2 BR112012008848A2 BR112012008848A BR112012008848A BR112012008848A2 BR 112012008848 A2 BR112012008848 A2 BR 112012008848A2 BR 112012008848 A BR112012008848 A BR 112012008848A BR 112012008848 A BR112012008848 A BR 112012008848A BR 112012008848 A2 BR112012008848 A2 BR 112012008848A2
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- vitro
- induced pluripotent
- vivo method
- stem cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/065—Modulators of histone acetylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/09—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells
- C12N2506/094—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells from keratinocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/28—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas. as cinéticas lentas e eficiência baixa dos métodos de reprogramação para gerar células tranco humanas pluripotentes induzidas (ipscs) impõem limitações maiores na sua utilidade em aplicações biomédicas. aqui nós descrevemos uma aproximação química que dramaticamente melhora (>200 vezes) a eficiência da geração de ipsc a partir de fibroblastos humanos, dentro de sete dias de tratamento. isto fornecerá uma base para o desenvolvimento métodos não virais mais seguros, mais eficientes para a reprogramação de células somáticas humanas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25254809P | 2009-10-16 | 2009-10-16 | |
PCT/US2010/052896 WO2011047300A1 (en) | 2009-10-16 | 2010-10-15 | Induction of pluripotent cells |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012008848A2 true BR112012008848A2 (pt) | 2019-09-24 |
Family
ID=43876590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012008848A BR112012008848A2 (pt) | 2009-10-16 | 2010-10-15 | composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas |
Country Status (12)
Country | Link |
---|---|
US (4) | US9005968B2 (pt) |
EP (3) | EP3235901B1 (pt) |
JP (6) | JP5808331B2 (pt) |
CN (3) | CN113621576A (pt) |
AU (1) | AU2010306627B2 (pt) |
BR (1) | BR112012008848A2 (pt) |
CA (3) | CA3194845A1 (pt) |
ES (2) | ES2938049T3 (pt) |
HK (1) | HK1175811A1 (pt) |
MX (2) | MX337982B (pt) |
RU (1) | RU2012117719A (pt) |
WO (1) | WO2011047300A1 (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102027105B (zh) | 2008-03-17 | 2015-03-11 | 斯克里普斯研究所 | 用于产生诱导的多能干细胞的组合化学遗传方法 |
US8906677B2 (en) | 2008-12-17 | 2014-12-09 | The Scripps Research Institute | Generation and maintenance of stem cells |
ES2938049T3 (es) * | 2009-10-16 | 2023-04-04 | Scripps Research Inst | Inducción de células pluripotentes |
CA2777710C (en) * | 2009-11-04 | 2021-02-23 | Cellular Dynamics International, Inc. | Episomal reprogramming with chemicals |
CA2800498C (en) | 2010-03-31 | 2021-11-16 | The Scripps Research Institute | Reprogramming cells |
ES2685171T3 (es) | 2010-06-14 | 2018-10-05 | The Scripps Research Institute | Reprogramación de células a un nuevo destino |
EP2611902A4 (en) | 2010-09-01 | 2014-03-26 | Whitehead Biomedical Inst | COMPOSITIONS AND METHODS FOR EMT MODULATION AND ITS APPLICATIONS |
CN114164167A (zh) * | 2010-12-22 | 2022-03-11 | 菲特治疗公司 | 用于单细胞分选与增强ipsc重新编程的细胞培养平台 |
WO2013086570A1 (en) * | 2011-12-13 | 2013-06-20 | Flinders University Of South Australia | Method of producing multipotent stem cells |
CN102604894B (zh) * | 2012-02-29 | 2014-07-30 | 中国科学院广州生物医药与健康研究院 | 用于制备神经干细胞的培养基及其用途 |
US20150017134A1 (en) * | 2012-03-01 | 2015-01-15 | Whitehead Institute For Biomedical Research | Emt-inducing transcription factors cooperate with sox9 |
WO2014034952A1 (ja) * | 2012-09-03 | 2014-03-06 | 国立大学法人九州大学 | がんに対する免疫療法の有効性の予測方法 |
US10724005B2 (en) | 2012-09-28 | 2020-07-28 | Scripps Health | Methods of differentiating stem cells into chondrocytes |
CN110139130B (zh) * | 2012-10-12 | 2022-09-20 | 佳能株式会社 | 流传输数据的方法、发送和接收视频数据的方法和设备 |
WO2014070797A1 (en) * | 2012-10-29 | 2014-05-08 | Scripps Health | Methods of producing pluripotent stem cells from chondrocytes |
JPWO2014058080A1 (ja) * | 2012-11-30 | 2016-09-05 | 国立研究開発法人理化学研究所 | 体細胞のリプログラミングを亢進させる方法、及び細胞作製キット |
JP6509126B2 (ja) * | 2013-01-09 | 2019-05-08 | インターナショナル ステム セル コーポレイション | 皮膚の再生を促進する小分子 |
SG11201606934SA (en) | 2014-03-04 | 2016-09-29 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
SG11201706041XA (en) | 2015-01-26 | 2017-08-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
EP3770252A1 (en) | 2015-01-26 | 2021-01-27 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
EP3272858A4 (en) * | 2015-03-18 | 2018-08-08 | ONO Pharmaceutical Co., Ltd. | Method for producing naïve pluripotent stem cells |
BR112018001232A2 (pt) | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 que expressa células-tronco hematopoéticas e usos |
CN117737124A (zh) | 2015-10-16 | 2024-03-22 | 菲特治疗公司 | 用于诱导和维护基态多能性的平台 |
AU2016349504B2 (en) | 2015-11-04 | 2023-02-09 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
US10858628B2 (en) | 2015-11-04 | 2020-12-08 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
ES2908707T3 (es) | 2016-01-08 | 2022-05-03 | Evia Life Sciences Inc | Procedimiento para producir células madre/precursoras hepáticas a partir de células hepáticas maduras utilizando un compuesto de bajo peso molecular |
JP7134416B2 (ja) * | 2016-10-28 | 2022-09-12 | 国立研究開発法人国立がん研究センター | ヒト肝前駆細胞の調製方法 |
KR102107602B1 (ko) * | 2017-05-29 | 2020-05-08 | 한양대학교 산학협력단 | 인간 성체 간세포 리프로그래밍 배지 조성물 |
CN110832069B (zh) * | 2017-05-31 | 2023-06-20 | 北昊干细胞与再生医学研究院有限公司 | 用于化学诱导的谱系重编程的方法 |
CN107326007B (zh) * | 2017-08-07 | 2020-06-12 | 南开大学 | 利用巴豆酸激活Zscan4等二细胞期基因并延长端粒,提高化学诱导重编程效率的方法 |
WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
CN108251377B (zh) * | 2018-01-16 | 2021-08-27 | 内蒙古大学 | 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法 |
JPWO2019151386A1 (ja) | 2018-01-31 | 2021-01-07 | 富士フイルム株式会社 | 細胞の製造方法 |
CA3116184A1 (en) * | 2018-10-15 | 2020-04-23 | Cynity Co., Ltd. | Method for producing stem/precursor cells, by using low molecular weight compound, from cells derived from endodermal tissue or organ |
JPWO2020213725A1 (pt) * | 2019-04-17 | 2020-10-22 | ||
US11801304B2 (en) | 2020-02-19 | 2023-10-31 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof |
WO2022072883A1 (en) * | 2020-10-02 | 2022-04-07 | Fate Therapeutics, Inc. | Improved reprogramming, maintenance and preservation for induced pluripotent stem cells |
EP4170018A1 (en) * | 2021-10-20 | 2023-04-26 | Roslin Technologies Limited | Ipsc induction and progeny derivation |
WO2023067090A1 (en) * | 2021-10-20 | 2023-04-27 | Roslin Technologies Limited | Ipsc induction and progeny derivation |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0641781B1 (en) | 1991-09-06 | 2000-07-26 | Yoshitomi Pharmaceutical Industries, Ltd. | 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof |
US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
EP0710283A4 (en) * | 1993-07-22 | 1997-07-02 | Merck & Co Inc | THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL |
US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
US20030059913A1 (en) | 1995-11-20 | 2003-03-27 | Walter Weyler | Novel Microorganisms with ability to degrade indole and novel enzymes therefrom |
GB9807935D0 (en) | 1998-04-14 | 1998-06-10 | Univ Edinburgh | Lineage specific cells and progenitor cells |
US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
SI0956865T2 (sl) | 1996-08-12 | 2011-04-29 | Mitsubishi Pharma Corp | Zdravila, ki obsegajo inhibitor Rho-kinaze |
US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
CA2292339A1 (en) | 1997-06-13 | 1998-12-17 | Ludwig Institute For Cancer Research | Smad6 and uses thereof |
US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US20060263382A1 (en) | 1998-06-20 | 2006-11-23 | Richard Hotchkiss | Membrane-permeant peptide complexes for treatment of sepsis |
AU773012B2 (en) | 1998-07-24 | 2004-05-13 | Carnegie Institution Of Washington | Method for maintenance and propagation of germline stem cells using members of the TGF-beta family of growth factors |
WO2000078351A1 (fr) | 1999-06-18 | 2000-12-28 | Mitsubishi Pharma Corporation | Promoteurs de l'osteogenese |
US6730293B1 (en) | 1999-08-24 | 2004-05-04 | Cellgate, Inc. | Compositions and methods for treating inflammatory diseases of the skin |
AU6865100A (en) | 1999-09-02 | 2001-04-10 | Mitsubishi Pharma Corporation | Osteogenesis promoting agents |
US20020142457A1 (en) | 1999-12-28 | 2002-10-03 | Akihiro Umezawa | Cell having the potentiality of differentiation into cardiomyocytes |
JP2002184539A (ja) | 2000-12-14 | 2002-06-28 | Auto Network Gijutsu Kenkyusho:Kk | コネクタ |
AR035791A1 (es) | 2001-03-23 | 2004-07-14 | Bayer Corp | Compuesto n,n-diheterociclico de amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y proceso para la preparacion del compuesto |
AU2002245709A1 (en) | 2001-03-23 | 2002-10-08 | Bayer Corporation | Rho-kinase inhibitors |
JP2003097552A (ja) | 2001-09-21 | 2003-04-03 | Nsk Ltd | 摩擦付加装置および直動案内装置 |
US20030062225A1 (en) | 2001-10-03 | 2003-04-03 | Stucky Paul A. | Elevator load bearing assembly having a detectable element that is indicative of local strain |
KR20100013352A (ko) | 2001-10-31 | 2010-02-09 | 알콘, 인코퍼레이티드 | 뼈 형태발생 단백질(bmp), bmp 수용체 및 bmp 결합 단백질 및 녹내장 진단 및 치료에서 그의 용도 |
ATE554169T1 (de) | 2001-11-02 | 2012-05-15 | Giuliani Int Ltd | Smad7-inhibitoren zur behandlung von krankheiten des zns |
AU2003202263A1 (en) | 2002-01-10 | 2003-07-30 | Bayer Healthcare Ag | Roh-kinase inhibitors |
US6943172B2 (en) | 2002-01-23 | 2005-09-13 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
CA2473510A1 (en) | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
AU2003220935A1 (en) | 2002-04-03 | 2003-10-13 | Sumitomo Pharmaceuticals Company, Limited. | Benzamide derivatives |
GB0210539D0 (en) | 2002-05-08 | 2002-06-19 | Univ Edinburgh | Control of es cell self renewal and lineage specification, and medium therefor |
US20040039796A1 (en) | 2002-08-08 | 2004-02-26 | Virtual Radio, Inc. | Personalized cyber disk jockey and Internet radio advertising |
EP1562935B1 (de) | 2002-10-28 | 2006-09-06 | Bayer HealthCare AG | Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren |
JP2006517234A (ja) | 2003-02-10 | 2006-07-20 | アムジエン・インコーポレーテツド | バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用 |
AU2003901099A0 (en) | 2003-03-11 | 2003-03-27 | Es Cell International Pte Ltd. | Methods of inducing differentiation of stem cells |
US20070010008A1 (en) | 2005-06-29 | 2007-01-11 | Tissuetech, Inc. | Ex vivo expansion of primary animal cells |
WO2005084158A2 (en) | 2003-06-20 | 2005-09-15 | The Regents Of The University Of California | Polypeptide transduction and fusogenic peptides |
US7727762B2 (en) | 2003-10-03 | 2010-06-01 | Keiichi Fukuda | Method of inducing the differentiation of stem cells into myocardial cells |
JP4110324B2 (ja) | 2003-10-15 | 2008-07-02 | 宇部興産株式会社 | 新規インダゾール誘導体 |
WO2005038010A2 (en) | 2003-10-16 | 2005-04-28 | The University Court Of The University Of Edinburgh | Control of es cell self-renewal and lineage specification, and medium therefor |
AU2004291559B2 (en) | 2003-11-19 | 2008-10-16 | Australian Stem Cell Centre Limited | Methods for producing blood products from pluripotent cells in cell culture |
US20070269412A1 (en) | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
EP1713775A4 (en) | 2004-01-30 | 2009-08-12 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
AU2005241009A1 (en) | 2004-04-21 | 2005-11-17 | Mcmaster University | Myosin light chain kinase inhibitors and their use |
US20060024634A1 (en) | 2004-07-28 | 2006-02-02 | 3M Innovative Properties Company | Self-ligating orthodontic appliance with clip |
EP1791952A4 (en) | 2004-08-13 | 2008-06-11 | Univ Georgia Res Found | COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS |
US20080268533A1 (en) | 2004-08-25 | 2008-10-30 | University Of Georgia Research Foundation, Inc. | Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells |
US20060182724A1 (en) | 2005-02-15 | 2006-08-17 | Riordan Neil H | Method for expansion of stem cells |
CN101313065A (zh) | 2005-08-01 | 2008-11-26 | 纽珀滕索有限公司 | 具有恢复的潜能的重编程序细胞的生产 |
CA2621161A1 (en) | 2005-09-08 | 2007-03-15 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Methods for promoting stem cell proliferation and survival |
GB0523039D0 (en) * | 2005-11-11 | 2005-12-21 | Univ Edinburgh | Reprogramming and genetic modification of cells |
EP4223769A3 (en) | 2005-12-13 | 2023-11-01 | Kyoto University | Nuclear reprogramming factor |
US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
JPWO2007088651A1 (ja) | 2006-02-01 | 2009-06-25 | 国立大学法人 東京大学 | TGF−βシグナル阻害剤と抗腫瘍剤の組み合せ使用 |
US7541186B2 (en) | 2006-02-22 | 2009-06-02 | University Of Washington | Method of generating human retinal progenitors from embryonic stem cells |
EP1999249B8 (en) | 2006-03-30 | 2012-02-15 | The University Court Of The University of Edinburgh | Culture medium containing kinase inhibitors. and uses thereof |
GB0615327D0 (en) | 2006-03-30 | 2006-09-13 | Univ Edinburgh | Culture medium containing kinase inhibitors and uses thereof |
US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
US20070259423A1 (en) | 2006-05-02 | 2007-11-08 | Jon Odorico | Method of differentiating stem cells into cells of the endoderm and pancreatic lineage |
CA2656398A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
JP4960450B2 (ja) | 2006-07-14 | 2012-06-27 | ノバルティス アーゲー | Alk−5阻害剤としてのピリミジン誘導体 |
JP2008099662A (ja) * | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | 幹細胞の培養方法 |
GB0622395D0 (en) | 2006-11-09 | 2006-12-20 | Univ Cambridge Tech | Methods relating to pluripotent cells |
JP5419279B2 (ja) * | 2007-01-17 | 2014-02-19 | ウィスコンシン アラムニ リサーチ ファンデーション | 改良された幹細胞の培養 |
US20100172883A1 (en) | 2007-01-19 | 2010-07-08 | Bruneau Benoit Gaetan | Methods of generating cardiomyocytes |
CN101641436A (zh) | 2007-01-30 | 2010-02-03 | 佐治亚大学研究基金会 | 用于产生内胚层和中胚层细胞系及多能游走细胞(mmc)的早期中胚层细胞即稳定的中内胚层细胞群 |
WO2008105630A1 (en) | 2007-02-27 | 2008-09-04 | Procell Therapeutics Inc. | Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells |
EP2131840B1 (en) | 2007-03-07 | 2018-10-17 | MEI Pharma, Inc. | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
WO2008126932A2 (en) | 2007-04-09 | 2008-10-23 | Riken | Epigenetical regulation of brain plasticity |
US8648069B2 (en) * | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
DK2173863T3 (en) * | 2007-06-29 | 2019-01-21 | Fujifilm Cellular Dynamics Inc | Automated method and apparatus for embryonic stem cell culture |
WO2009032456A2 (en) | 2007-08-01 | 2009-03-12 | Primegen Biotech Llc | Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state |
MX2010002242A (es) | 2007-08-31 | 2010-06-01 | Whitehead Biomedical Inst | Estimulación de ruta wnt en reprogramacion de celulas somaticas. |
WO2009057831A1 (ja) | 2007-10-31 | 2009-05-07 | Kyoto University | 核初期化方法 |
WO2009061442A1 (en) | 2007-11-06 | 2009-05-14 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells |
JP4604076B2 (ja) | 2007-11-07 | 2010-12-22 | 国立大学法人静岡大学 | 燃料電池用電解質膜 |
WO2009073523A2 (en) | 2007-11-29 | 2009-06-11 | Children's Hospital Of Orange County | De-differentiation of human cells |
EP2227241A1 (en) | 2007-11-30 | 2010-09-15 | Cytomatrix PTY LTD | Methods of inducing pluripotency involving sox2 protein |
US20110190730A1 (en) | 2007-11-30 | 2011-08-04 | Cytomatrix Pty Ltd | Methods of inducing pluripotency involving oct4 protein |
JP2009215191A (ja) * | 2008-03-07 | 2009-09-24 | Keio Gijuku | 神経損傷治療剤及び神経損傷治療方法 |
CN102027105B (zh) | 2008-03-17 | 2015-03-11 | 斯克里普斯研究所 | 用于产生诱导的多能干细胞的组合化学遗传方法 |
US8298825B1 (en) * | 2008-08-25 | 2012-10-30 | The General Hospital Corporation | TGF-beta receptor inhibitors to enhance direct reprogramming |
SG196784A1 (en) | 2008-12-03 | 2014-02-13 | Scripps Research Inst | Stem cell cultures |
US8906677B2 (en) | 2008-12-17 | 2014-12-09 | The Scripps Research Institute | Generation and maintenance of stem cells |
US20120122212A1 (en) | 2009-03-06 | 2012-05-17 | Marica Grskovic | Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells |
US9005975B2 (en) * | 2009-05-29 | 2015-04-14 | Kyoto University | Method for selecting clone of induced pluripotent stem cells |
ES2726766T3 (es) * | 2009-08-07 | 2019-10-09 | Univ Kyoto | Método para el desarrollo eficiente de células madre pluripotentes inducidas |
ES2938049T3 (es) * | 2009-10-16 | 2023-04-04 | Scripps Research Inst | Inducción de células pluripotentes |
ES2533581T3 (es) | 2010-03-05 | 2015-04-13 | Texas Heart Institute | ETS2 y Mesp1 generadores de progenitores cardíacos a partir de fibroblastos |
CA2800498C (en) | 2010-03-31 | 2021-11-16 | The Scripps Research Institute | Reprogramming cells |
US9905105B1 (en) | 2016-12-01 | 2018-02-27 | General Electric Company | Method of increasing sensing device noticeability upon low battery level |
-
2010
- 2010-10-15 ES ES17173120T patent/ES2938049T3/es active Active
- 2010-10-15 CN CN202110535275.5A patent/CN113621576A/zh active Pending
- 2010-10-15 CA CA3194845A patent/CA3194845A1/en active Pending
- 2010-10-15 WO PCT/US2010/052896 patent/WO2011047300A1/en active Application Filing
- 2010-10-15 EP EP17173120.1A patent/EP3235901B1/en active Active
- 2010-10-15 US US13/500,373 patent/US9005968B2/en active Active
- 2010-10-15 MX MX2012004283A patent/MX337982B/es active IP Right Grant
- 2010-10-15 CN CN201610220657.8A patent/CN105861446B/zh active Active
- 2010-10-15 ES ES10824189.4T patent/ES2638464T3/es active Active
- 2010-10-15 CA CA2777720A patent/CA2777720C/en active Active
- 2010-10-15 CA CA3091210A patent/CA3091210C/en active Active
- 2010-10-15 EP EP10824189.4A patent/EP2488630B1/en active Active
- 2010-10-15 EP EP22205835.6A patent/EP4206319A1/en active Pending
- 2010-10-15 JP JP2012534403A patent/JP5808331B2/ja active Active
- 2010-10-15 AU AU2010306627A patent/AU2010306627B2/en active Active
- 2010-10-15 BR BR112012008848A patent/BR112012008848A2/pt not_active IP Right Cessation
- 2010-10-15 RU RU2012117719/10A patent/RU2012117719A/ru not_active Application Discontinuation
- 2010-10-15 CN CN201080056597.1A patent/CN102741394B/zh active Active
-
2012
- 2012-04-12 MX MX2021014919A patent/MX2021014919A/es unknown
-
2013
- 2013-03-06 HK HK13102807.4A patent/HK1175811A1/zh unknown
-
2015
- 2015-03-03 US US14/637,089 patent/US9909105B2/en active Active
- 2015-09-08 JP JP2015176558A patent/JP6189384B2/ja active Active
-
2017
- 2017-08-02 JP JP2017149760A patent/JP6491284B2/ja active Active
-
2018
- 2018-01-19 US US15/875,928 patent/US11046933B2/en active Active
-
2019
- 2019-02-28 JP JP2019035239A patent/JP6683857B2/ja active Active
-
2020
- 2020-03-26 JP JP2020055640A patent/JP7160855B2/ja active Active
-
2021
- 2021-05-14 US US17/320,676 patent/US20210403878A1/en active Pending
-
2022
- 2022-10-13 JP JP2022164465A patent/JP2022185128A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012008848A2 (pt) | composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas | |
BR112013004514A2 (pt) | diferenciação das células-tronco embrionárias humanas | |
BR112015017174A2 (pt) | preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico | |
BR112013004616A2 (pt) | diferenciação das células tronco embrionárias humanas | |
BR112012028855A2 (pt) | diferenciação das células-tronco embrionárias humanas | |
BRPI0514641A (pt) | cultivação das células tronco embriÈnica humana | |
BR112012017267A2 (pt) | ácidos graxos de cadeia ramificada dispersos e produção biológica dos mesmos | |
BRPI0619794B8 (pt) | Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas | |
BR112014006244A2 (pt) | microrganismos e métodos para produzir alcenos | |
BR122020000182B1 (pt) | Neurônios dopaminérgicos do mesencéfalo para enxerto | |
BR112015022770A8 (pt) | meio e sistema de cultivo da célula livre de xenógeno, livre de albumina, forma concentrada, métodos de diferenciação de células-tronco pluripotentes humanas, para a produção de mesenquimoangioblastos e sistema definido de cultivo da célula para diferenciação hematoendotelial das células- tronco pluripotentes humanas | |
BR112012015727A2 (pt) | diferenciacao de celulas-tronco embrionarias humanas | |
BR112013002981A2 (pt) | processo de transfecção de plantas. | |
HRP20200279T1 (hr) | Sulfatirani alginat hidrogelova za kulturu stanica i terapiju | |
BR112014010448A2 (pt) | microorganismos e métodos para a produção de caprolactona | |
BR112013018751A2 (pt) | método de cultura de célula animal | |
HRP20150594T1 (hr) | Stromalne matiäśne stanice | |
BR112012015119A2 (pt) | "ácidos graxos de cadeia ramificada e produção biológica dos mesmos". | |
BR112015009229A2 (pt) | composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada | |
BR112022010822A2 (pt) | Métodos para cultivar células, preparação de hidrolisado a partir de células e aplicações dos mesmos | |
BR112013020737A2 (pt) | grânulo e respectiva composição, métodos para extrair compostos almejados a partir de biomassa, para aglomerar biomassa seca e triturada e para gerar grânulos, processo para extrair um ou mais compostos almejados a partir de biomassa de cultura de suspensão, aparelho para aglomerar cultura de suspensão e dispositivo para avaliar a resistência compressiva de grânulo algáceo e kit | |
BRPI0514453A (pt) | sistema aquoso de liberação de enzima | |
BR112014027333A2 (pt) | composição, métodos de tratamento ou melhora, de prevenção, e, de diagnóstico de uma condição prejudicial que está associada com o teor elevado de sulfato de heparano em um indivíduo que foi o receptor de um órgão, tecido ou células transplantados | |
AR059193A1 (es) | Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias | |
BR0315975A (pt) | Usos de uma quantidade de um modulador e de um bloqueador de dc-sign, composição farmacêutica, métodos para identificar um modulador e um bloqueador de dc-sign, bloqueador de dc-sign isolado, e, método para alvejar uma molécula objeto a uma célula que expressa um receptore de dc-sign |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |